KR102806918B1 - 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 - Google Patents

접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 Download PDF

Info

Publication number
KR102806918B1
KR102806918B1 KR1020237009552A KR20237009552A KR102806918B1 KR 102806918 B1 KR102806918 B1 KR 102806918B1 KR 1020237009552 A KR1020237009552 A KR 1020237009552A KR 20237009552 A KR20237009552 A KR 20237009552A KR 102806918 B1 KR102806918 B1 KR 102806918B1
Authority
KR
South Korea
Prior art keywords
protein
kinase
beta
alpha
protein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237009552A
Other languages
English (en)
Korean (ko)
Other versions
KR20230044024A (ko
Inventor
다니엘 제이. 섹스톤
말리니 비스와나탄
라이언 파우셋
트립티 가우르
Original Assignee
다케다 파머수티컬 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 파머수티컬 컴패니 리미티드 filed Critical 다케다 파머수티컬 컴패니 리미티드
Priority to KR1020257015097A priority Critical patent/KR20250073510A/ko
Publication of KR20230044024A publication Critical patent/KR20230044024A/ko
Application granted granted Critical
Publication of KR102806918B1 publication Critical patent/KR102806918B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020237009552A 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 Active KR102806918B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257015097A KR20250073510A (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662395712P 2016-09-16 2016-09-16
US62/395,712 2016-09-16
US201762518492P 2017-06-12 2017-06-12
US62/518,492 2017-06-12
PCT/US2017/051749 WO2018053244A1 (en) 2016-09-16 2017-09-15 Protein biomarkers for diseases associated with the contact activation system
KR1020197010801A KR102513485B1 (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010801A Division KR102513485B1 (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257015097A Division KR20250073510A (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커

Publications (2)

Publication Number Publication Date
KR20230044024A KR20230044024A (ko) 2023-03-31
KR102806918B1 true KR102806918B1 (ko) 2025-05-14

Family

ID=59974881

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237009552A Active KR102806918B1 (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
KR1020197010801A Active KR102513485B1 (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
KR1020257015097A Pending KR20250073510A (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197010801A Active KR102513485B1 (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
KR1020257015097A Pending KR20250073510A (ko) 2016-09-16 2017-09-15 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커

Country Status (12)

Country Link
US (2) US11815516B2 (https=)
EP (1) EP3513196B1 (https=)
JP (4) JP7225089B2 (https=)
KR (3) KR102806918B1 (https=)
CN (2) CN109716138B (https=)
AU (3) AU2017325983B2 (https=)
BR (1) BR112019005179A2 (https=)
CA (1) CA3037154A1 (https=)
CO (1) CO2019002599A2 (https=)
IL (2) IL265195B2 (https=)
MX (2) MX2019002932A (https=)
WO (1) WO2018053244A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017325986B2 (en) 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
CN113092769A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液补体c4-a及其多肽片段在过敏性疾病中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501184A (ja) * 2008-08-28 2012-01-19 ワイス・エルエルシー 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001174463A (ja) * 1999-12-17 2001-06-29 Hsp Research Institute Inc 自己免疫疾患又は腫瘍の診断方法
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
JP4399593B2 (ja) * 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007059966A1 (en) * 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
US8883153B2 (en) * 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US9102942B2 (en) * 2010-02-04 2015-08-11 EWHA University—Industry Collaboration Foundation Pharmaceutical composition for inhibiting abnormal proliferation of cells
JP2011226882A (ja) * 2010-04-19 2011-11-10 Kitasato Institute 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
WO2012170947A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
US20130102486A1 (en) * 2011-10-20 2013-04-25 The Board Of Trustees Of The Leland Stanford Junior University Perp as a prognostic and diagnostic marker for dysplasia and cancer
EP2946206B1 (en) * 2013-01-20 2019-01-09 Dyax Corp. Evaluation, assays and treatment of pkal-mediated disorders
WO2014113712A1 (en) * 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
JP6757252B2 (ja) * 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
CA2927695C (en) * 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
AU2015209481C1 (en) * 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
EP3132053B1 (en) * 2014-04-15 2020-09-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Differential diagnosis of eczema and psoriasis
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
AU2017325986B2 (en) 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501184A (ja) * 2008-08-28 2012-01-19 ワイス・エルエルシー 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENRIETTE FARKAS et al., Clinic Rev Allerg Immunol., (2016.05.), pp 1-12.*

Also Published As

Publication number Publication date
JP7693788B2 (ja) 2025-06-17
AU2024201506A1 (en) 2024-03-28
CN109716138A (zh) 2019-05-03
WO2018053244A1 (en) 2018-03-22
AU2024201506B2 (en) 2025-12-18
EP3513196B1 (en) 2026-02-25
AU2017325983A1 (en) 2019-03-21
BR112019005179A2 (pt) 2019-07-02
CA3037154A1 (en) 2018-03-22
IL265195A (en) 2019-05-30
AU2017325983B2 (en) 2023-12-07
JP2024023904A (ja) 2024-02-21
JP7412616B2 (ja) 2024-01-12
IL265195B1 (en) 2024-10-01
EP3513196A1 (en) 2019-07-24
MX2019002932A (es) 2019-07-15
IL265195B2 (en) 2025-02-01
CO2019002599A2 (es) 2019-03-29
MX2024009782A (es) 2024-08-19
KR102513485B1 (ko) 2023-03-23
JP2019529906A (ja) 2019-10-17
US11815516B2 (en) 2023-11-14
JP7225089B2 (ja) 2023-02-20
NZ751193A (en) 2024-02-23
NZ792394A (en) 2025-07-25
JP2023058608A (ja) 2023-04-25
JP2025124852A (ja) 2025-08-26
KR20230044024A (ko) 2023-03-31
EP3513196C0 (en) 2026-02-25
KR20190053913A (ko) 2019-05-20
US20240142468A1 (en) 2024-05-02
KR20250073510A (ko) 2025-05-27
IL315799A (en) 2024-11-01
AU2026201253A1 (en) 2026-03-12
CN109716138B (zh) 2023-10-03
US20210285962A1 (en) 2021-09-16
CN117192130A (zh) 2023-12-08

Similar Documents

Publication Publication Date Title
JP7516451B2 (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
JP7692508B2 (ja) 接触活性化系に関連する疾患の代謝物バイオマーカー
AU2026201253A1 (en) Protein biomarkers for diseases associated with the contact activation system
HK40102769A (zh) 用於接触活化系统相关的疾病的蛋白生物标记
EA045712B1 (ru) Белковые биомаркеры заболеваний, ассоциированных с контактной системой активации
WO2024003617A2 (en) Protein biomarkers for lanadelumab treatment
HK40102782A (zh) 用於与接触活化系统相关的疾病的代谢产物生物标记

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230320

Application number text: 1020197010801

Filing date: 20190415

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230530

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20240102

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0701 Decision of registration after re-examination

Patent event date: 20250305

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
PG1601 Publication of registration